Stockscreener 앱 받기
536.12
0.62%
3.30
전일 마감가:
$532.82
열려 있는:
$533.83
하루 거래량:
526.88K
Relative Volume:
1.21
시가총액:
$23.50B
수익:
$3.13B
순이익/손실:
$1.27B
주가수익비율:
20.32
EPS:
26.3851
순현금흐름:
$1.12B
1주 성능:
+12.12%
1개월 성능:
+13.19%
6개월 성능:
+32.37%
1년 성능:
+75.55%
1일 변동 폭
$533.83
$543.37
1주일 범위
$495.50
$548.12
52주 변동 폭
$266.98
$548.12
유나이티드 테라퓨틱스 Stock (UTHR) Company Profile
명칭
United Therapeutics Corp
전화
(301) 608-9292
주소
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, ZTS, HLN, TEVA
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
536.12 | 23.50B | 3.13B | 1.27B | 1.12B | 26.39 |
|
TAK
Takeda Pharmaceutical Co Adr
|
17.77 | 56.14B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.62 | 48.81B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.03 | 44.67B | 14.54B | 2.22B | 2.58B | 0.4879 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.57 | 33.27B | 17.41B | 1.43B | 1.00B | 1.2182 |
유나이티드 테라퓨틱스 Stock (UTHR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-20 | 개시 | Wells Fargo | Underweight |
| 2025-09-26 | 개시 | RBC Capital Mkts | Outperform |
| 2025-06-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-25 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-07-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | 업그레이드 | Goldman | Sell → Neutral |
| 2024-02-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2022-12-06 | 개시 | UBS | Buy |
| 2022-12-05 | 개시 | Goldman | Sell |
| 2022-10-11 | 개시 | Morgan Stanley | Overweight |
| 2022-09-20 | 재확인 | BofA Securities | Underperform |
| 2022-09-19 | 재개 | Wedbush | Outperform |
| 2022-02-11 | 개시 | BTIG Research | Neutral |
| 2021-07-14 | 업그레이드 | Argus | Hold → Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-02-01 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-06-25 | 재확인 | H.C. Wainwright | Neutral |
| 2020-03-10 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-02-27 | 업그레이드 | Cowen | Market Perform → Outperform |
| 2020-01-31 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2019-12-03 | 개시 | BofA/Merrill | Underperform |
| 2019-08-01 | 업그레이드 | Jefferies | Underperform → Hold |
| 2019-08-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | 업그레이드 | UBS | Sell → Neutral |
| 2019-05-09 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2018-08-08 | 다운그레이드 | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | 업그레이드 | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | 재확인 | Barclays | Underweight |
| 2018-01-18 | 재개 | Credit Suisse | Underperform |
| 2017-12-27 | 재확인 | Wedbush | Outperform |
| 2017-04-27 | 재확인 | Wedbush | Outperform |
| 2017-03-30 | 개시 | UBS | Sell |
| 2017-03-16 | 개시 | Credit Suisse | Underperform |
모두보기
유나이티드 테라퓨틱스 주식(UTHR)의 최신 뉴스
United Therapeutics Stock Surges 32% in 6 Months: Here's Why - Yahoo Finance
UBS raises United Therapeutics stock price target to $705 on catalysts - Investing.com Nigeria
Cantor Fitzgerald raises United Therapeutics stock price target to $625 - Investing.com Nigeria
Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Stock - MarketBeat
Inhaled IPF drug from United Therapeutics slows lung scarring in trial - Stock Titan
United Therapeutics: Ralinepag Is The Ultimate Defense Against Yutrepia (Rating Upgrade) - Seeking Alpha
Capital Fund Management S.A. Purchases 20,410 Shares of United Therapeutics Corporation $UTHR - MarketBeat
UTHR Stock Price, Quote & Chart | UNITED THERAPEUTICS CORP (NASDAQ:UTHR) - ChartMill
Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock - MarketBeat
United Therapeutics CEO Martine A. Rothblatt Executes Stock Sales - TradingView
United Therapeutics Corp (UTHR) Shares Up 3.04% on Mar 10 - GuruFocus
United Therapeutics (NASDAQ:UTHR) Sets New 1-Year HighHere's What Happened - MarketBeat
United Therapeutics stock hits all-time high at 537.83 USD - Investing.com
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains? - Yahoo Finance
Grantham Mayo Van Otterloo & Co. LLC Acquires 6,079 Shares of United Therapeutics Corporation $UTHR - MarketBeat
Insider Sell: Judy Olian Sells 200 Shares of United Therapeutics Corp (UTHR) - GuruFocus
United Therapeutics Corp (UTHR) Shares Up 8.91% on Mar 9 - GuruFocus
United Therapeutics Launches $1.5 Billion Accelerated Share Repurchases With Citi Under $2 Billion Buyback - TradingView
United Therapeutics CEO Martine A. Rothblatt Sells 9,500 Shares - TradingView
United Therapeutics stock jumps 9% on $2B buyback program - Investing.com
United Therapeutics stock buyback signals franchise confidence, TD Cowen says - Investing.com Nigeria
United Therapeutics (NASDAQ:UTHR) Shares Gap UpStill a Buy? - MarketBeat
United Therapeutics authorizes $2 billion buyback program - Investing.com
United Therapeutics sends $1.5B upfront for stock, $500M left - Stock Titan
First Trust Advisors LP Trims Stake in United Therapeutics Corporation $UTHR - MarketBeat
Rhenman & Partners Asset Management AB Buys Shares of 8,000 United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Shares Positive Study Results for its Bioengineered Liver - Medical Product Outsourcing
Ray Kurzweil Sells 4,910 Shares of United Therapeutics Corp - GuruFocus
United Therapeutics (NASDAQ:UTHR) EVP Paul Mahon Sells 8,300 Shares - MarketBeat
United Therapeutics (NASDAQ:UTHR) Director Sells $978,840.00 in Stock - MarketBeat
United Therapeutics (UTHR) Receives Increased Price Target from UBS | UTHR Stock News - GuruFocus
Fisher Asset Management LLC Buys 4,987 Shares of United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics Corp (NASDAQ:UTHR) Emerges as a Peter Lynch-Style GARP Candidate - ChartMill
United Therapeutics Shares Drop 1.69% as Revenue Shortfall Outweighs Profit Surpass; Trading Volume Places 493rd - Bitget
AustralianSuper Pty Ltd Cuts Stake in United Therapeutics Corporation $UTHR - MarketBeat
United Therapeutics pill shows late-stage success in rare lung disease PAH - IndiaMedToday
TD Cowen reiterates United Therapeutics stock Buy on ralinepag trial success - Investing.com India
Insider Sell: Jan Malcolm Sells Shares of United Therapeutics Co - GuruFocus
United Therapeutics Chairperson & CEO Martine A. Rothblatt Sells 9,500 Shares - TradingView
United Therapeutics CEO to give update at Leerink healthcare conference - Stock Titan
Leerink raises United Therapeutics stock price target on trial data - Investing.com South Africa
Leerink raises United Therapeutics stock price target on trial data By Investing.com - Investing.com India
Jefferies raises United Therapeutics stock price target on trial data By Investing.com - Investing.com Australia
Jefferies raises United Therapeutics stock price target on trial data - Investing.com South Africa
Insider Sell: Judy Olian Sells Shares of United Therapeutics Cor - GuruFocus
United Therapeutics Hits Day High with 13% Surge in Strong Intraday Performance - Markets Mojo
H.C. Wainwright reiterates Buy on United Therapeutics stock - Investing.com South Africa
H.C. Wainwright reiterates Buy on United Therapeutics stock By Investing.com - Investing.com UK
United Therapeutics (UTHR): Investor Outlook With A 13% Upside Potential - DirectorsTalk Interviews
United Therapeutics Corporation Announces Ralinepag Achieved 55% Reduction in Risk of Clinical Worsening in Pivotal Pulmonary Arterial Hypertension Study, Delivering Exceptional, Highly Statistically Significant Efficacy - marketscreener.com
United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening - Benzinga
유나이티드 테라퓨틱스 (UTHR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.10%
1.57%
자본화:
|
볼륨(24시간):